Cargando…

Radiation therapy for primary orbital and ocular adnexal lymphoma

OBJECTIVE: To report the efficacy and toxicity of External beam Radiotherapy (EBRT) as a sole treatment for MALT and Follicular Primary Orbital and Ocular adnexal Lymphoma (POOAL) METHODS: Retrospective review of all POOAL patients treated with EBRT utilizing megavoltage photon or electron beam radi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira-Da Silva, Maria Valeria, Di Nicola, Maria Laura, Altomare, Filiberto, Xu, Wei, Tsang, Richard, Laperriere, Normand, Krema, Hatem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637715/
https://www.ncbi.nlm.nih.gov/pubmed/36353653
http://dx.doi.org/10.1016/j.ctro.2022.10.001
_version_ 1784825248062898176
author Pereira-Da Silva, Maria Valeria
Di Nicola, Maria Laura
Altomare, Filiberto
Xu, Wei
Tsang, Richard
Laperriere, Normand
Krema, Hatem
author_facet Pereira-Da Silva, Maria Valeria
Di Nicola, Maria Laura
Altomare, Filiberto
Xu, Wei
Tsang, Richard
Laperriere, Normand
Krema, Hatem
author_sort Pereira-Da Silva, Maria Valeria
collection PubMed
description OBJECTIVE: To report the efficacy and toxicity of External beam Radiotherapy (EBRT) as a sole treatment for MALT and Follicular Primary Orbital and Ocular adnexal Lymphoma (POOAL) METHODS: Retrospective review of all POOAL patients treated with EBRT utilizing megavoltage photon or electron beam radiotherapy between 2003 and 2015. Patient demographics, tumour extent and pathology, radiotherapy techniques, and treatment outcomes were reviewed. The actuarial rates of tumour control and radiation toxicities were calculated using Kaplan-Meier estimates. RESULTS: This study included 167 tumours, of which MALT lymphoma involved 149 (89 %). The conjunctiva and orbit were equally involved as the predominant site (48 %). Megavoltage photon radiotherapy was used in 60 % of predominantly orbital lymphoma and Electron beam with lens shielding in 77 % of the conjunctival lymphoma. The majority (95 %) were treated with a total dose of 25 Gy in 10 fractions. Local control rate was 98 % (CI: 93–100 %) at 5 years. The long-term RT toxicities included dry eye in 27 eyes (16 %) and cataract in 22 (13 %). None of the patients developed significant structural or functional radiation toxicity. CONCLUSION: External Beam Radiotherapy, with lens shielding whenever indicated, at a dose of 20–30 Gy delivered over 10–20 fractions is an efficacious and safe primary treatment option for POOAL lymphoma, with excellent local control and low incidence of late manageable ocular toxicities.
format Online
Article
Text
id pubmed-9637715
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-96377152022-11-08 Radiation therapy for primary orbital and ocular adnexal lymphoma Pereira-Da Silva, Maria Valeria Di Nicola, Maria Laura Altomare, Filiberto Xu, Wei Tsang, Richard Laperriere, Normand Krema, Hatem Clin Transl Radiat Oncol Article OBJECTIVE: To report the efficacy and toxicity of External beam Radiotherapy (EBRT) as a sole treatment for MALT and Follicular Primary Orbital and Ocular adnexal Lymphoma (POOAL) METHODS: Retrospective review of all POOAL patients treated with EBRT utilizing megavoltage photon or electron beam radiotherapy between 2003 and 2015. Patient demographics, tumour extent and pathology, radiotherapy techniques, and treatment outcomes were reviewed. The actuarial rates of tumour control and radiation toxicities were calculated using Kaplan-Meier estimates. RESULTS: This study included 167 tumours, of which MALT lymphoma involved 149 (89 %). The conjunctiva and orbit were equally involved as the predominant site (48 %). Megavoltage photon radiotherapy was used in 60 % of predominantly orbital lymphoma and Electron beam with lens shielding in 77 % of the conjunctival lymphoma. The majority (95 %) were treated with a total dose of 25 Gy in 10 fractions. Local control rate was 98 % (CI: 93–100 %) at 5 years. The long-term RT toxicities included dry eye in 27 eyes (16 %) and cataract in 22 (13 %). None of the patients developed significant structural or functional radiation toxicity. CONCLUSION: External Beam Radiotherapy, with lens shielding whenever indicated, at a dose of 20–30 Gy delivered over 10–20 fractions is an efficacious and safe primary treatment option for POOAL lymphoma, with excellent local control and low incidence of late manageable ocular toxicities. Elsevier 2022-10-08 /pmc/articles/PMC9637715/ /pubmed/36353653 http://dx.doi.org/10.1016/j.ctro.2022.10.001 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Pereira-Da Silva, Maria Valeria
Di Nicola, Maria Laura
Altomare, Filiberto
Xu, Wei
Tsang, Richard
Laperriere, Normand
Krema, Hatem
Radiation therapy for primary orbital and ocular adnexal lymphoma
title Radiation therapy for primary orbital and ocular adnexal lymphoma
title_full Radiation therapy for primary orbital and ocular adnexal lymphoma
title_fullStr Radiation therapy for primary orbital and ocular adnexal lymphoma
title_full_unstemmed Radiation therapy for primary orbital and ocular adnexal lymphoma
title_short Radiation therapy for primary orbital and ocular adnexal lymphoma
title_sort radiation therapy for primary orbital and ocular adnexal lymphoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637715/
https://www.ncbi.nlm.nih.gov/pubmed/36353653
http://dx.doi.org/10.1016/j.ctro.2022.10.001
work_keys_str_mv AT pereiradasilvamariavaleria radiationtherapyforprimaryorbitalandocularadnexallymphoma
AT dinicolamarialaura radiationtherapyforprimaryorbitalandocularadnexallymphoma
AT altomarefiliberto radiationtherapyforprimaryorbitalandocularadnexallymphoma
AT xuwei radiationtherapyforprimaryorbitalandocularadnexallymphoma
AT tsangrichard radiationtherapyforprimaryorbitalandocularadnexallymphoma
AT laperrierenormand radiationtherapyforprimaryorbitalandocularadnexallymphoma
AT kremahatem radiationtherapyforprimaryorbitalandocularadnexallymphoma